S1PR1 and VEGFR2 – a synergy that promotes tumor angiogenesis?

Vijay Avin Balaji Ragunathrao, Vigneshwaran Vellingiri, Mumtaz Anwar, Md Zahid Akhter, and Dolly Mehta

Department of Pharmacology and the Center for Lung and Vascular Biology, University of Illinois College of Medicine, Chicago, IL, USA

ABSTRACT
We have recently uncovered that endothelial cell (EC) S1PR1 controls the effectiveness of VEGFR2 driven tumor angiogenesis. By using tumor ECs, EC-S1PR1−/− mice and S1PR1 antagonist, we showed that VEGF-VEGFR2 pathway requires EC-S1PR1-induced signaling to efficiently drive tumor vascularization and growth, indicating combining S1PR1 antagonist with anti-VEGF/VEGFR2 therapy may eradicate resistant tumors.

Authors commentary
Assertione vascularization of tumors is a crucial factor responsible for tumor growth and metastasis which is mediated by VEGF-VEGFR2 (Vascular endothelial growth factor-VEGFR receptor 2) signaling.1 However, treatment with VEGF and VEGFR2 inhibitors has only been efficacious in some cancers and further it has been largely ineffective in preventing metastasis and recurrence of tumors.2 Studies show that other growth factors interacts with VEGF2 signaling which may dictate the outcome of VEGF2 angiogenic signaling.3 In this context, we surmised that other angiogenic pathways cooperates with VEGF-VEGFR2 signaling to efficiently drive VEGFR2 tumor vascularization and growth.

Sphingosine-1-phosphate receptor 1 (S1PR1) expressed on EC-surface, like VEGFR2, is shown to mediate tumor angiogenesis.4 Upon ligating sphingosine 1 Phosphate (SIP), S1PR1 stimulates heterotrimeric protein, Gi which in turn activates PI3-kinase/Akt/ERK signaling leading to EC survival.5 S1PR1-Gi cascade also activates the small GTPase Rac1, which is essential for EC migration.6,7 While a few studies showed that impairment of S1PR1 function reduced VEGF-induced angiogenesis8 others showed that loss of S1PR1 in ECs induced hyper-sprouting due to increased VEGFR2 activity.9

We demonstrated that endothelial S1PR1-cAbl1 signaling pathway prolonged VEGFR2 signaling augmenting thereby tumor angiogenesis and growth.10 While S1P and VEGF can both independently mediate angiogenesis through activation of their respective receptors, S1PR1 and VEGFR2 in ECs.4 We showed that VEGF alone was weakly angiogenic in S1PR1-depleted ECs corroborating the study shown by LaMontagne et al.8 indicating that, that S1PR1 was required for promoting VEGFR2 mediated ECs migration and angiogenesis. The importance of S1PR1/VEGFR2 interaction was evident in studies showing conditional deletion of S1PR1 in ECs markedly reduced VEGFR2 mediated tumor angiogenesis.10 These findings are in line with previous published studies, for example, S1PR1 facilitated VEGFR2 mediated migration of thyroid cancer cells4 while blockade of S1P using anti-SIP antibodies or S1PR1 antagonists prevented VEGF-induced tumor angiogenesis and growth.8,11 Thus, our study demonstrated that EC-S1PR1 controlled the efficiency of VEGFR2 signaling to drive the key tumor angiogenesis program, i.e. EC migration supporting tumor vessel vascularization and growth (Figure 1). However, a caveat of the Vijay Avin et al study was that animal model used did not allow an assessment of the role of S1PR1 enhancement of VEGFR2 angiogenic signaling in promoting tumor resistance to VEGFR2 based therapy which represent an attractive topic for future investigations.

The current dogma regarding VEGFR2 angiogenic signaling is that upon ligating VEGF the receptor is phosphorylated at tyrosine (Y) 1175.3 Y1175-phosphorylated VEGFR2 then internalizes and induces the activities of small GTPase Rac1, ERK and AKT for signaling angiogenesis.3 Thus, in contrast to S1PR1, internalized VEGFR2 drives angiogenesis. Additionally, a few studies showed that loss of VEGFR2 phosphorylation at Y951 residues (949 in mouse) blocked tumor metastasis.12 Vijay Avin et al demonstrated that S1PR1 inhibited VEGFR2 internalization by VEGF and in this case VEGF phosphorylated VEGFR2 at Y951. Cell-surface retained VEGFR2 persistently activated Rac1 following VEGF addition which in turn promoted EC migration to tumor for vascularization and growth. However, in the case of S1PR1 null tumor ECs, VEGF resulted activation of the canonical pathway in which VEGF induced phosphorylation of VEGFR2 at Y1175 was followed by internalization with the co-operative endocytic machinery leading to activation of ERK1/2/3.

S1PR1 couples with heterotrimeric GTP binding protein, Gi to induce downstream signaling.6 Using pertussis toxin which blocks Gi activity we showed that S1PR1 required Gi activity to control VEGFR2 phosphorylation at Y951. The tyrosine kinases, c-Src, FAK, and c-Abl can phosphorylate VEGFR2.3 We demonstrated that cAbl1, but not c-Src or FAK phosphorylated VEGFR2 at Y951 downstream of S1PR1 and Gi. c-Abl1 activity is known to
induce tumors, further highlighting the relevance of our findings.

The kinase activity of c-Abl1 is increased following binding to its substrate. In order to investigate whether S1PR1 mediated c-Abl activity by complexing it with Gi we performed co-immunoprecipitation assay. We demonstrated that VEGF2 interacted with cAbl1, and further that Gi was required for cAbl1 activation downstream of S1PR1. Moreover, siRNA-mediated knockdown of cAbl1 prevented VEGF2 phosphorylation at Y951 as well as Rac1 activation. Expression of Y951-phosphodefective VEGFR2 mutant also reduced cAbl1 phosphorylation in response to VEGF, suggesting an amplification mechanism of cAbl1 activation. In fact, neuropilin 1 receptor interacts with VEGFR2 by a mechanism involving cAbl1 phosphorylation of VEGF2 at Y951 supporting the findings of the current study.

Taken together, we showed that the VEGF-VEGFR2 pathway requires S1PR1-induced signaling in ECs to efficiently drive tumor vasculization and growth. S1PR1 functions via Gi to promote the activation of cAbl1 by VEGF. Activated cAbl1 induces phosphorylation of VEGFR2 at Y951, promoting receptor retention at the EC surface which in a sustained manner induces Rac1 activity and EC migration and tumor angiogenesis (Figure 1). Results from the present study suggest that a combination of S1PR1 antagonist with VEGF-VEGFR2 inhibitors could represent the first step toward treating VEGFR2 refractory tumors and prove relevant in other cancers driven by VEGF-VEGFR2 signaling.

Disclosure of potential conflicts of interest
No potential conflicts of interest were disclosed.

Funding
This work was supported by NIH grants HL84153 and HL060678 funded to DM.

ORCID
Vijay Avin Balaji Ragunathrao http://orcid.org/0000-0001-6032-4048

References
1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29(6Q):15–18. doi:10.1053/sonc.2002.37263.
2. Barber MC, Mauro MJ, Moslehi J. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Hematology Am Soc Hematol Educ Program. 2017;2017(1):110–114. doi:10.1182/asheducation-2017.1.110.
3. Olsson A-K, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling in control of vascular function. Nat Rev Mol Cell Biol. 2006;7(5):359–371. doi:10.1038/nrm1911.
4. Bergelin N, Lof C, Balthasar S, Kalhori V, Tornquist K. S1P1 and VEGFR-2 form a signaling complex with extracellularly regulated kinase 1/2 and protein kinase C-alpha regulating ML-1 thyroid carcinoma cell migration. Endocrinology. 2010;151(7):2994–3005. doi:10.1210/en.2009-1387.

5. Proia RL, Hla T. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest. 2015;125(4):1379–1387. doi:10.1172/JCI76369.

6. Saba JD, Hla T. Point-counterpoint of sphingosine 1-phosphate metabolism. Circ Res. 2004;94(6):724–734. doi:10.1161/01.RES.0000122383.60368.24.

7. Mehta D, Konstantoulaki M, Ahmmed GU, Malik AB. Sphingosine 1-phosphate-induced mobilization of intracellular Ca2+ mediates rac activation and adherens junction assembly in endothelial cells. J Biol Chem. 2005;280(17):17320–17328. doi:10.1074/jbc.M411674200.

8. LaMontagne K, Littlewood-Evans A, Schnell C, O’Reilly T, Wyder L, Sanchez T, Probst B, Butler J, Wood A, Liao G, et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 2006;66(1):221–231. doi:10.1158/0008-5472.CAN-05-2001.

9. Gaengel K, Niaudet C, Hagikura K, Laviña B, Mahl I, Hofmann J, Ebarasi L, Nyström S, Rymo S, Chen L, et al. The sphingosine-1-phosphate receptor S1P1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2. Dev Cell. 2012;23(3):587–599. doi:10.1016/j.devcel.2012.08.005.

10. Balaji Ragunathrao VA, Anwar M, Akhter MZ, Chavez A, Mao DY, Natarajan V, Lakshmikanthan S, Chrzanowska-Wodnicka M, Dudek AZ, Claesson-Welsh L, et al. Sphingosine-1-phosphate receptor 1 activity promotes tumor growth by amplifying VEGF-VEGFR2 angiogenic signaling. Cell Rep. 2019;29(3472–3487):e3474. doi:10.1016/j.celrep.2019.11.036.

11. Zhang L, Wang X, Bullock AJ, Callea M, Shah H, Song J, Moreno K, Visentin B, Deutschman D, Alsop DC, et al. Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI-resistant renal cancer. Clin Can Res. 2015;21(8):1925–1934. doi:10.1158/1078-0432.CCR-14-2031.

12. Matsumoto T, Bohman S, Dixelius J, Berge T, Dimberg A, Magnusson P, Wang L, Wikner C, Qi JH, Wernstedt C, et al. VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. Embo J. 2005;24(13):2342–2353. doi:10.1038/sj.emboj.7600709.

13. Vigneri P, Stagno F, Stella S, Cupri A, Forte S, Massimino M, Antolino A, Siragus S, Mannina D, Impera SS, i High BCR-ABL/GUS(IS) levels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib. Clin Can Res. 2017;23(23):7189–7198. doi:10.1158/1078-0432.CCR-17-0962.

14. Raimondi C, Fantin A, Lampropoulou A, Denti L, Chikh A, Ruhrberg C. Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cells. J Exp Med. 2014;211(6):1167–1183. doi:10.1084/jem.20132330.